---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039389"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:06:40.528035+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cogent Q2 net loss $44.1M, cash $350.9M, PEAK DCR 55%, FGFR2 candidate nominated

## Summary
- Cash & equivalents $350.9M at June 30 (up from $220.3M on Mar 31); funded into 2026.
- Net loss Q2 2023: $44.1M vs $34.9M Q2 2022; R&D $38.9M vs $29.5M.
- Phase 3 PEAK lead-in data: 55% DCR; 100% DCR and 17% ORR in evaluable 2nd-line GIST patients.
- Selected FGFR2 kinase inhibitor as first internally developed candidate; preclinical data planned for 2H2023.
- Initial SUMMIT (NonAdvSM) and updated APEX (AdvSM) data expected in second half of 2023.

## SEC filing metadata
- accession: 0000950170-23-039389
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/0000950170-23-039389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/cogt-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039389
- JSON: https://secwatch.observer/filing/0000950170-23-039389.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039389.txt

## Key facts
- Earnings Releases
  Cogent Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income $44.1 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: $44.1 million
  - Result: reported results
  source text: Net loss was $44.1 million for the second quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/0000950170-23-039389-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.